Based on the Krystal Biotech Inc stock forecast from 0 analysts, the average analyst target price for Krystal Biotech Inc is not available over the next 12 months. Krystal Biotech Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Krystal Biotech Inc is Slightly Bullish , which is based on 6 positive signals and 4 negative signals. At the last closing, Krystal Biotech Inc’s stock price was EUR 185.90. Krystal Biotech Inc’s stock price has changed by +7.27% over the past week, +17.84% over the past month and +95.68% over the last year.
No recent analyst target price found for Krystal Biotech Inc
No recent average analyst rating found for Krystal Biotech Inc
Company Overview Krystal Biotech Inc
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. Read Less
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epider...Read More
Frequently Asked Questions About Krystal Biotech Inc (4KB:F) Stock
Stock Target Advisor's fundamental analysis for Krystal Biotech Inc's stock is Slightly Bullish .
Unfortunately we do not have enough data on 4KB:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 4KB:F's stock to indicate what its average analyst target is.
4KB:F stock's Price/Earning ratio is 96.10.
Our analysis grades 4KB:F stock's Price / Earning ratio at F. This means that 4KB:F stock's Price/Earning ratio is above 87% of the stocks in the Biotechnology sector in the F exchange.
Based on this 4KB:F may be a overvalued for its sector.
The last closing price of 4KB:F's stock was EUR 185.90.
The most recent market capitalization for 4KB:F is EUR 4.65B.
Unfortunately we do not have enough analyst data on 4KB:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Krystal Biotech Inc's stock.
As per our most recent records Krystal Biotech Inc has 229 Employees.
Krystal Biotech Inc's registered address is 2100 Wharton Street, Pittsburgh, PA, United States, 15203.
You can get more information about it from Krystal Biotech Inc's website at https://www.krystalbio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Krystal Biotech Inc (4KB:F) Stock
Stock Target Advisor's fundamental analysis for Krystal Biotech Inc's stock is Slightly Bullish .
Unfortunately we do not have enough data on 4KB:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 4KB:F's stock to indicate what its average analyst target is.
4KB:F stock's Price/Earning ratio is 96.10.
Our analysis grades 4KB:F stock's Price / Earning ratio at F. This means that 4KB:F stock's Price/Earning ratio is above 87% of the stocks in the Biotechnology sector in the F exchange.
Based on this 4KB:F may be a overvalued for its sector.
The last closing price of 4KB:F's stock was EUR 185.90.
The most recent market capitalization for 4KB:F is EUR 4.65B.
Unfortunately we do not have enough analyst data on 4KB:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Krystal Biotech Inc's stock.
As per our most recent records Krystal Biotech Inc has 229 Employees.
Krystal Biotech Inc's registered address is 2100 Wharton Street, Pittsburgh, PA, United States, 15203.
You can get more information about it from Krystal Biotech Inc's website at https://www.krystalbio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 4KB:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
